Peters Marion G, Locarnini Stephen
Dr Peters is a professor of medicine and chief of hepatology research in the Department of Medicine at the University of California in San Francisco, California. Dr Locarnini is a professor of microbiology and immunology at the University of Melbourne and is director of the WHO Regional Reference Laboratory for Hepatitis B within the Victorian Infectious Diseases Reference Laboratory at the Doherty Institute in Melbourne, Australia.
Gastroenterol Hepatol (N Y). 2017 Jun;13(6):348-356.
Chronic hepatitis B (CHB) affects over 350 million individuals worldwide and is the most common cause of liver cancer. In the United States, CHB affects at least 2 to 3 million individuals, and current therapies can control the disease but not cure it. There are over 30 new molecules being studied in CHB in preclinical to phase 2 studies, targeting specific parts of the hepatitis B virus (HBV) life cycle and the host immune response. When discussing new therapies for CHB, it is critical to understand both the various phases of CHB and the life cycle of HBV. This article will discuss both of these issues, as well as mechanisms of action of potential therapies and possible ways to combine such therapies in the various phases of CHB.
慢性乙型肝炎（CHB）在全球影响着超过3.5亿人，是肝癌最常见的病因。在美国，CHB至少影响200万至300万人，目前的疗法可以控制病情，但无法治愈。有30多种新分子正在进行慢性乙型肝炎的临床前到2期研究，针对乙肝病毒（HBV）生命周期的特定部分以及宿主免疫反应。在讨论慢性乙型肝炎的新疗法时，了解慢性乙型肝炎的各个阶段以及HBV的生命周期至关重要。本文将讨论这两个问题，以及潜在疗法的作用机制和在慢性乙型肝炎各阶段联合此类疗法的可能方法。
